Dual-energy computed tomography has limited diagnostic sensitivity for short-term gout

Ertao Jia, Junqing Zhu, Wenhui Huang, Xiaoguang Chen, Juan Li, Ertao Jia, Junqing Zhu, Wenhui Huang, Xiaoguang Chen, Juan Li

Abstract

The aim of this study was to discuss the diagnostic value of dual-energy computed tomography (DECT) in patients with gout during different disease phases. Two hundred twenty-one patients (136 with gout and 85 with other arthritic diseases) were recruited to the study. Arthrosis pain was evaluated in all patients by DECT scans. We calculated the sensitivity and specificity of DECT for the diagnosis of gout, including the first onset period, less than 24 months period, and more than 24 months period. We then investigated the related risk factors of urate crystals volume in the foot. The diagnostic sensitivity of DECT in the first onset, less than 24 months, and more than 24 months groups was 35.71, 61.54, and 92.86%, respectively. The overall sensitivity and specificity values were 80.88 and 88.24%, respectively. The multilinear regression analysis showed that longer disease duration (P = 0.001) and higher serum uric acid (SUA) (P = 0.001) were the two important predictive factors of the monosodium urate (MSU) crystal volume in the foot. DECT provides good diagnostic accuracy for detection of MSU crystal deposits in gout patients. However, DECT has limited diagnostic sensitivity for short-term gout patients, especially for the first onset patients. Longer disease duration and higher SUA were predictive factors of MSU crystal volume.

Keywords: Clinical trials; Disease duration; Dual-energy computed tomography; Gout.

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Bland–Altman plots of differences between readers. Differences in MSU crystal volumes measured by two independent readers plotted as a function of the mean MSU crystal volume. The blue solid horizontal line represents the mean difference (i.e., bias) in volumes measured by the two readers. The dashed horizontal lines represent the observed 95% limits of agreement (−0.04 to 0.06 cm3)

References

    1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136–3141. doi: 10.1002/art.30520.
    1. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67:960–966. doi: 10.1136/ard.2007.076232.
    1. Kim SC, Schmidt BM, Franklin JM, Liu J, Solomon DH, Schneeweiss S. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken) 2013;65:2008–2014. doi: 10.1002/acr.22067.
    1. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67:1310–1316. doi: 10.1136/ard.2007.081604.
    1. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(679–687):e1.
    1. Underwood M. Diagnosis and management of gout. BMJ. 2006;332:1315–1319. doi: 10.1136/bmj.332.7553.1315.
    1. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895–900. doi: 10.1002/art.1780200320.
    1. Spermon J, Van Dijke CF. Dual energy CT: added value in gouty arthritis. JBR-BTR. 2013;96:34–37.
    1. Girish G, Melville DM, Kaeley GS, Brandon CJ, Goyal JR, Jacobson JA, Jamadar DA. Imaging appearances in gout. Arthritis. 2013;2013:673401. doi: 10.1155/2013/673401.
    1. Mallinson PI, Reagan AC, Coupal T, Munk PL, Ouellette H, Nicolaou S. The distribution of urate deposition within the extremities in gout: a review of 148 dual-energy CT cases. Skelet Radiol. 2014;43:277–281. doi: 10.1007/s00256-013-1771-8.
    1. Bongartz T, Glazebrook KN, Kavros SJ, Murthy NS, Merry SP, Franz WB, 3rd, Michet CJ, Veetil BM, Davis JM, 3rd, Mason TG, 2nd, et al. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis. 2015;74:1072–1077. doi: 10.1136/annrheumdis-2013-205095.
    1. Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJEM, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789–1798. doi: 10.1136/annrheumdis-2015-208237.
    1. Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, Schumacher HR, Dalbeth N. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis. 2015;74:1868–1874. doi: 10.1136/annrheumdis-2014-205431.
    1. Rigby AS, Wood PH. Serum uric acid levels and gout: what does this herald for the population? Clin Exp Rheumatol. 1994;12:395–400.
    1. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65:1301–1311. doi: 10.1136/ard.2006.055251.
    1. Sivera F, Andres M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73:328–335. doi: 10.1136/annrheumdis-2013-203325.
    1. Vazquez-Mellado J, Hernandez-Cuevas CB, Alvarez-Hernandez E, Ventura-Rios L, Pelaez-Ballestas I, Casasola-Vargas J, Garcia-Mendez S, Burgos-Vargas R. The diagnostic value of the proposal for clinical gout diagnosis (CGD) Clin Rheumatol. 2012;31:429–434. doi: 10.1007/s10067-011-1873-4.
    1. Glazebrook KN, Kakar S, Ida CM, Laurini JA, Moder KG, Leng S. False-negative dual-energy computed tomography in a patient with acute gout. J Clin Rheumatol. 2012;18:138–141. doi: 10.1097/RHU.0b013e318253aa5e.
    1. Melzer R, Pauli C, Treumann T, Krauss B. Gout tophus detection-a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum. 2014;43:662–665. doi: 10.1016/j.semarthrit.2013.11.002.
    1. Englund C, Loren CE, Grabbe C, Varshney GK, Deleuil F, Hallberg B, Palmer RH. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature. 2003;425:512–516. doi: 10.1038/nature01950.
    1. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13–23. doi: 10.1038/nrrheum.2012.143.
    1. Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983;42(Suppl 1):12–15. doi: 10.1136/ard.42.Suppl_1.12.
    1. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis. 2005;64:179–182. doi: 10.1136/ard.2003.018457.
    1. Wu H, Xue J, Ye L, Zhou Q, Shi D, Xu R. The application of dual-energy computed tomography in the diagnosis of acute gouty arthritis. Clin Rheumatol. 2014;33:975–979. doi: 10.1007/s10067-014-2606-2.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi